220 related articles for article (PubMed ID: 15916424)
1. Targeting and inhibition of cell growth by an engineered dendritic nanodevice.
Thomas TP; Majoros IJ; Kotlyar A; Kukowska-Latallo JF; Bielinska A; Myc A; Baker JR
J Med Chem; 2005 Jun; 48(11):3729-35. PubMed ID: 15916424
[TBL] [Abstract][Full Text] [Related]
2. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy.
Majoros IJ; Thomas TP; Mehta CB; Baker JR
J Med Chem; 2005 Sep; 48(19):5892-9. PubMed ID: 16161993
[TBL] [Abstract][Full Text] [Related]
3. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality.
Majoros IJ; Myc A; Thomas T; Mehta CB; Baker JR
Biomacromolecules; 2006 Feb; 7(2):572-9. PubMed ID: 16471932
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity analysis of poly(amidoamine) dendrimer-based mono- and multifunctional nanodevices by capillary electrophoresis.
Shi X; Majoros IJ; Patri AK; Bi X; Islam MT; Desai A; Ganser TR; Baker JR
Analyst; 2006 Mar; 131(3):374-81. PubMed ID: 16496045
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates.
Myc A; Douce TB; Ahuja N; Kotlyar A; Kukowska-Latallo J; Thomas TP; Baker JR
Anticancer Drugs; 2008 Feb; 19(2):143-9. PubMed ID: 18176110
[TBL] [Abstract][Full Text] [Related]
6. HPLC analysis of PAMAM dendrimer based multifunctional devices.
Islam MT; Majoros IJ; Baker JR
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Aug; 822(1-2):21-6. PubMed ID: 15950555
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of G5 PAMAM dendrimer containing daunorubicin for targeting cancer cells.
Yue Y; Eun JS; Lee MK; Seo SY
Arch Pharm Res; 2012 Feb; 35(2):343-9. PubMed ID: 22370789
[TBL] [Abstract][Full Text] [Related]
8. Targeted dendrimeric anticancer prodrug: a methotrexate-folic acid-poly(amidoamine) conjugate and a novel, rapid, "one pot" synthetic approach.
Zhang Y; Thomas TP; Desai A; Zong H; Leroueil PR; Majoros IJ; Baker JR
Bioconjug Chem; 2010 Mar; 21(3):489-95. PubMed ID: 20128612
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.
Kukowska-Latallo JF; Candido KA; Cao Z; Nigavekar SS; Majoros IJ; Thomas TP; Balogh LP; Khan MK; Baker JR
Cancer Res; 2005 Jun; 65(12):5317-24. PubMed ID: 15958579
[TBL] [Abstract][Full Text] [Related]
10. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
Patri AK; Kukowska-Latallo JF; Baker JR
Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
[TBL] [Abstract][Full Text] [Related]
11. Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modified multi-walled carbon nanotubes.
Wen S; Liu H; Cai H; Shen M; Shi X
Adv Healthc Mater; 2013 Sep; 2(9):1267-76. PubMed ID: 23447549
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer cells with biotin-dendrimer conjugates.
Yang W; Cheng Y; Xu T; Wang X; Wen LP
Eur J Med Chem; 2009 Feb; 44(2):862-8. PubMed ID: 18550227
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional PAMAM dendrimer conjugates of folic acid and methotrexate with defined ratio.
Zong H; Thomas TP; Lee KH; Desai AM; Li MH; Kotlyar A; Zhang Y; Leroueil PR; Gam JJ; Banaszak Holl MM; Baker JR
Biomacromolecules; 2012 Apr; 13(4):982-91. PubMed ID: 22360561
[TBL] [Abstract][Full Text] [Related]
14. Design considerations for PAMAM dendrimer therapeutics.
Goonewardena SN; Kratz JD; Zong H; Desai AM; Tang S; Emery S; Baker JR; Huang B
Bioorg Med Chem Lett; 2013 May; 23(10):2872-5. PubMed ID: 23583511
[TBL] [Abstract][Full Text] [Related]
15. Dendrimer-based BH3 conjugate that targets human carcinoma cells.
Myc A; Patri AK; Baker JR
Biomacromolecules; 2007 Oct; 8(10):2986-9. PubMed ID: 17877400
[TBL] [Abstract][Full Text] [Related]
16. Encapsulation of 2-methoxyestradiol within multifunctional poly(amidoamine) dendrimers for targeted cancer therapy.
Wang Y; Guo R; Cao X; Shen M; Shi X
Biomaterials; 2011 Apr; 32(12):3322-9. PubMed ID: 21315444
[TBL] [Abstract][Full Text] [Related]
17. Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent.
Zhang Y; Thomas TP; Lee KH; Li M; Zong H; Desai AM; Kotlyar A; Huang B; Holl MM; Baker JR
Bioorg Med Chem; 2011 Apr; 19(8):2557-64. PubMed ID: 21459000
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the internalization of targeted dendrimers and dendrimer-entrapped gold nanoparticles into cancer cells.
Shi X; Wang SH; Lee I; Shen M; Baker JR
Biopolymers; 2009 Nov; 91(11):936-42. PubMed ID: 19603491
[TBL] [Abstract][Full Text] [Related]
19. Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic Acid-multiwalled carbon nanotube conjugate.
Das M; Datir SR; Singh RP; Jain S
Mol Pharm; 2013 Jul; 10(7):2543-57. PubMed ID: 23683251
[TBL] [Abstract][Full Text] [Related]
20. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic.
Thomas TP; Huang B; Choi SK; Silpe JE; Kotlyar A; Desai AM; Zong H; Gam J; Joice M; Baker JR
Mol Pharm; 2012 Sep; 9(9):2669-2676. PubMed ID: 22827500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
